Obesity Treatment Market Primed for Growth; Viking and Amgen Emerging as Top Stocks to Watch
-
Obesity treatment market has multi-billion dollar potential, poised to be the next big wave in healthcare investing after immuno-oncology
-
2 biopharma stocks recommended Viking Therapeutics and Amgen, both with promising obesity drug candidates
-
Viking's VK2809 shows promise for treating NASH and type 2 diabetes; VK2735 targets obesity
-
Amgen has 2 obesity drug candidates - AMG 133 and AMG 786 - with data readouts coming in 2023/2024
-
Analyst sees obesity drugs compensating for fading mature products in Amgen's portfolio, keeping revenue growth steady